Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Bladder Cancer

Free Subscription Articles published in Int Urol Nephrol Retrieve available abstracts of 72 articles: HTML format

Single Articles

September 2025
1. LIU X, Wang Y, Wang Z, Shao B, et al
   Chemotherapy-enhanced endoscopic submucosal En Bloc dissection vs. conventional TURBT for NMIBC: a comparative study.
   Int Urol Nephrol. 2025;57:2755-2765.
   PubMed     Abstract available
   
   
   August 2025
2. YILDIZ AK, Bayraktar A, Kacan T, Demir DO, et al
   Two different protocols in single, immediate, postoperative intravesical chemotherapy after transurethral resection in suspected, low-risk, non-muscle-invasive bladder cancer.
   Int Urol Nephrol. 2025 Aug 28. doi: 10.1007/s11255-025-04767.
   PubMed     Abstract available
   
   
   
3. XIANG X, Mei X, Song X, Pan B, et al
   High-density lectin microarray uncovers stage-specific plasma glycoprofiling signatures for non-muscle-invasive and muscle-invasive bladder cancer.
   Int Urol Nephrol. 2025 Aug 10. doi: 10.1007/s11255-025-04708.
   PubMed     Abstract available
   
   
   
4. IOSSA V, Olivieri A, Buonopane R, Di Girolamo A, et al
   Assessment of quality of life in patients undergoing hyperthermic intravesical chemotherapy (HIVEC) using EORTC questionnaires (QLQ-C30 and QLQ-NMIBC24).
   Int Urol Nephrol. 2025;57:2415-2423.
   PubMed     Abstract available
   
   
   July 2025
5. MANTICA G, Calarco A, Leonardi R
   Artificial intelligence for rare bladder cancer variants: a new hope for detection?
   Int Urol Nephrol. 2025 Jul 4. doi: 10.1007/s11255-025-04647.
   PubMed    
   
   
   
6. LI Y, Sun X, Wang Y, Ma B, et al
   Prognostic factors in T1 high-grade urothelial carcinoma of the bladder with lymphovascular invasion: a retrospective cohort study.
   Int Urol Nephrol. 2025;57:2099-2105.
   PubMed     Abstract available
   
   
   
7. GUBBIOTTI M, Rubilotta E, Bacchiani M, Cocci A, et al
   Intravesical administration of highly concentrated hyaluronic acid and chondroitin sulfate as add-on therapy for chemical cystitis induced by Bacillus Calmette-Guerin (BCG) immunotherapy.
   Int Urol Nephrol. 2025;57:2033-2039.
   PubMed     Abstract available
   
   
   June 2025
8. LI JKM, Wang L, Tse RTH, Leung CH, et al
   A cross-sectional study on the effects of intravesical BCG on urinary microbiota in bladder cancer patients.
   Int Urol Nephrol. 2025 Jun 30. doi: 10.1007/s11255-025-04607.
   PubMed     Abstract available
   
   
   
9. SOLTANI S, Rahimi HR, Mottaghi M, Tavakkoli M, et al
   Comparison of microRNA-21 expression in bladder cancer tumor with normal-appearing adjacent tissue and healthy controls.
   Int Urol Nephrol. 2025 Jun 13. doi: 10.1007/s11255-025-04581.
   PubMed     Abstract available
   
   
   
10. MA W, Shui Y, Wang G, Zhang X, et al
    Previous maximal transurethral resection of bladder tumor lead to unfavorable perioperative outcomes following radical cystectomy.
    Int Urol Nephrol. 2025;57:1817-1826.
    PubMed     Abstract available
    
    
    May 2025
11. ZHANG S, Chen C, Mo C, Fan N, et al
    A clinical study of RC48-ADC combined with PD-1 inhibitor in bladder preservation therapy for muscle-invasive bladder cancer (MIBC)-based on real-world data analysis.
    Int Urol Nephrol. 2025 May 14. doi: 10.1007/s11255-025-04567.
    PubMed     Abstract available
    
    
    
12. LONGONI M, Marmiroli A, Falkenbach F, Le QC, et al
    Oncological outcomes after non-surgical management versus radical cystectomy in non-organ-confined non-urothelial bladder cancer.
    Int Urol Nephrol. 2025 May 7. doi: 10.1007/s11255-025-04566.
    PubMed     Abstract available
    
    
    
13. MAHRAN SE, Salem SE, Sabry NA, Farid SF, et al
    The nephroprotective effect of metformin with cisplatin in bladder cancer: randomized clinical trial.
    Int Urol Nephrol. 2025 May 3. doi: 10.1007/s11255-025-04505.
    PubMed     Abstract available
    
    
    
14. GAO S, Liu T, Liu Q
    DNMT1 promotes bladder cancer progression and immune escape by inhibiting MYH11 expression by methylating its promoter.
    Int Urol Nephrol. 2025 May 2. doi: 10.1007/s11255-025-04527.
    PubMed     Abstract available
    
    
    
15. PLAGE H, Furlano K, Hofbauer S, Rossner F, et al
    PLAP expression is linked to invasive tumor growth in urothelial carcinoma of the bladder.
    Int Urol Nephrol. 2025;57:1381-1388.
    PubMed     Abstract available
    
    
    April 2025
16. WONG TR, Sun C, Ledesma B, Isali I, et al
    The role of angiogenin in bladder cancer: where are we in 2025?
    Int Urol Nephrol. 2025 Apr 22. doi: 10.1007/s11255-025-04517.
    PubMed     Abstract available
    
    
    
17. WU YJ, Chang SJ, Huang YS, Chai CY, et al
    Overexpression of BMAL-1 is related to progression of urothelial carcinoma in arsenic exposure area.
    Int Urol Nephrol. 2025;57:1175-1187.
    PubMed     Abstract available
    
    
    March 2025
18. CHEN CC, Yen TH, Li JR, Chen CJ, et al
    Artificial intelligence algorithms enhance urine cytology reporting confidence in postoperative follow-up for upper urinary tract urothelial carcinoma.
    Int Urol Nephrol. 2025;57:801-808.
    PubMed     Abstract available
    
    
    February 2025
19. FAN H, Chen W, Guo W, Han J, et al
    Intravesical gemcitabine versus anthracyclines for primary and first recurrent non-muscle-invasive bladder cancer: a single-center retrospective study over 10 years.
    Int Urol Nephrol. 2025 Feb 21. doi: 10.1007/s11255-025-04413.
    PubMed     Abstract available
    
    
    
20. STROJNY Z, Kawka E, Strojny M, Kucz-Chrostowska A, et al
    Exploring the impact of chronotype, chrononutrition and lifestyle on bladder cancer.
    Int Urol Nephrol. 2025 Feb 21. doi: 10.1007/s11255-025-04371.
    PubMed     Abstract available
    
    
    
21. CONTIERI R, Guigui A, Gondran-Tellier B, Basile G, et al
    Key strategies for reducing recurrence in T1 bladder cancer. Evidence from a retrospective multicenter European study.
    Int Urol Nephrol. 2025 Feb 11. doi: 10.1007/s11255-025-04416.
    PubMed     Abstract available
    
    
    January 2025
22. ZHAO L, Tian G, Wang X, Li L, et al
    Clinical significance of a new early diagnostic model for bladder cancer based on genome-wide microarray profiling of serum exosomal lncRNAs.
    Int Urol Nephrol. 2025 Jan 7. doi: 10.1007/s11255-024-04360.
    PubMed     Abstract available
    
    
    
23. AKDAS EM, Culha MM, Telli E, Bosnali E, et al
    The effect of intravesical chemohyperthermia with mitomycin in non-muscle-invasive bladder tumour patients who cannot tolerate BCG treatment or recur after treatment and refuse cystectomy.
    Int Urol Nephrol. 2025;57:63-69.
    PubMed     Abstract available
    
    
    December 2024
24. SEVEN I, Akturk Esen S, Sekmek S, Karahan I, et al
    Clinicopathological features and treatment outcomes of urothelial carcinoma variant histologies and non-urothelial bladder cancers.
    Int Urol Nephrol. 2024 Dec 27. doi: 10.1007/s11255-024-04341.
    PubMed     Abstract available
    
    
    
25. KAYRA MV, Deniz ME, Ozer C, Guvel S, et al
    Estimation of Physiologic Ability and Surgical Stress (E-PASS) predicts postoperative complications after radical cystectomy.
    Int Urol Nephrol. 2024;56:3743-3749.
    PubMed     Abstract available
    
    
    November 2024
26. IVANIC D, Dug H, Jagodic S, Delibegovic S, et al
    Preoperative neutrophil-to-lymphocyte ratio (NLR) value as a predictor of recurrence of non-muscle-invasive bladder cancer.
    Int Urol Nephrol. 2024 Nov 27. doi: 10.1007/s11255-024-04297.
    PubMed     Abstract available
    
    
    August 2024
27. XIONG Y, Zhao T, Li C
    Application value of extreme flexion and abduction hip combined with stirrup-shaped multifunctional leg frame in blocking obturator nerve reflex in transurethral resection of bladder tumor.
    Int Urol Nephrol. 2024;56:2503-2511.
    PubMed     Abstract available
    
    
    
28. LUO Q, Xu L, Lin C, Chao H, et al
    The clinical study of urinary flow parameters after drag-and-bond anastomosis for ileal orthotopic neobladder reconstruction.
    Int Urol Nephrol. 2024;56:2615-2621.
    PubMed     Abstract available
    
    
    July 2024
29. LIANG H, Sun H, Chen J
    A modified ureteroileal anastomosis can reduce ureteroileal anastomotic stricture after ileal conduit.
    Int Urol Nephrol. 2024;56:2235-2241.
    PubMed     Abstract available
    
    
    
30. REFUGIA JM, Thakker PU, Roebuck E, Brownstead HA, et al
    Surgeon-administered regional nerve blocks during radical cystectomy: a feasibility study.
    Int Urol Nephrol. 2024;56:2227-2234.
    PubMed     Abstract available
    
    
    June 2024
31. DAVID J, Pathak RA
    Editorial comment for "Surgeon-administered regional nerve blocks during radical cystectomy: a feasibility study".
    Int Urol Nephrol. 2024;56:1937-1938.
    PubMed    
    
    
    May 2024
32. YAN T, Zhou W, Li C
    Discovery of a T cell proliferation-associated regulator signature correlates with prognosis risk and immunotherapy response in bladder cancer.
    Int Urol Nephrol. 2024 May 24. doi: 10.1007/s11255-024-04086.
    PubMed     Abstract available
    
    
    
33. ZHU W, Wu L, Xie W, Zhang G, et al
    Comparison of morbidity and mortality after radical cystectomy between individuals older and younger than 80 years: a systematic review and meta-analysis.
    Int Urol Nephrol. 2024;56:1525-1535.
    PubMed     Abstract available
    
    
    April 2024
34. BERNARDINO RM, Wettstein M, Garisto J, Fleshner NE, et al
    Editorial comment to the paper: RE: low cubilin/myeloperoxidase's ratio as a promising biomarker for prognosis of high grade T1 bladder cancer.
    Int Urol Nephrol. 2024 Apr 2. doi: 10.1007/s11255-024-04035.
    PubMed    
    
    
    
35. LI B, Lin Y, Yang Y, Wang Z, et al
    Patients with periodontitis might increase the risk of urologic cancers: a bidirectional two-sample Mendelian randomization study.
    Int Urol Nephrol. 2024;56:1243-1251.
    PubMed     Abstract available
    
    
    
36. JAKUS D, Solic I, Borovac JA, Situm M, et al
    The influence of the initial clinical presentation of upper tract urothelial carcinoma on histopathological tumor features.
    Int Urol Nephrol. 2024;56:1335-1341.
    PubMed     Abstract available
    
    
    March 2024
37. SILVA MEDEIROS M, Botelho de Carvalho LA, Alves M, Papoila A, et al
    Low Cubilin/Myeloperoxidase ratio as a promising biomarker for prognosis of high-grade T1 bladder cancer.
    Int Urol Nephrol. 2024 Mar 26. doi: 10.1007/s11255-024-03971.
    PubMed     Abstract available
    
    
    
38. ZHAI H, Wang Y, Chen Z, Wang Z, et al
    Clinicopathological characteristics, surgical treatments, and oncological outcomes of localized primary unifocal urothelial carcinoma involving the ureterovesical junction.
    Int Urol Nephrol. 2024;56:941-955.
    PubMed     Abstract available
    
    
    
39. MOEEN AM, Hameed DA, Mostafa MG, Shaban SH, et al
    Lymphadenectomy before and after radical cystectomy: does this affect the radicality? A prospective randomized comparative study.
    Int Urol Nephrol. 2024;56:965-972.
    PubMed     Abstract available
    
    
    February 2024
40. BRISUDA A, Hornak J, Zemlickova B, Hacek J, et al
    Intravesical thermochemotherapy in the treatment of high-risk and very high-risk non-muscle-invasive urothelial bladder cancer: a single-arm study.
    Int Urol Nephrol. 2024 Feb 8. doi: 10.1007/s11255-023-03924.
    PubMed     Abstract available
    
    
    
41. LI Y, Xu H, Lin T, Zhang J, et al
    Preoperative low plasma creatine kinase levels predict worse survival outcomes in bladder cancer after radical cystectomy.
    Int Urol Nephrol. 2024 Feb 5. doi: 10.1007/s11255-024-03957.
    PubMed     Abstract available
    
    
    
42. KACZMAREK K, Plage H, Furlano K, Hofbauer S, et al
    Loss of Upk1a and Upk1b expression is linked to stage progression in urothelial carcinoma of the bladder.
    Int Urol Nephrol. 2024;56:499-508.
    PubMed     Abstract available
    
    
    
43. BAHADORI A, Bray G, Rukin N
    Secondary tumours in orthotopic neobladder using isolated gut segment post radical cystectomy for urothelial carcinoma: a systematic review.
    Int Urol Nephrol. 2024;56:519-525.
    PubMed     Abstract available
    
    
    
44. WANG S, Wei Z, Shu H, Xu Y, et al
    Early diagnosis and prognostic potential of RAC3 in bladder tumor.
    Int Urol Nephrol. 2024;56:475-482.
    PubMed     Abstract available
    
    
    January 2024
45. WU J, Cheng X, Yang H, Xiao S, et al
    Geriatric nutritional risk index as a prognostic factor in elderly patients with non-muscle-invasive bladder cancer: a propensity score-matched study.
    Int Urol Nephrol. 2024 Jan 4. doi: 10.1007/s11255-023-03905.
    PubMed     Abstract available
    
    
    
46. SAITO T, Matsumoto K, Tanaka N, Fukumoto K, et al
    Prognostic impact of tumor ureteral invasion on recurrence after radical cystectomy.
    Int Urol Nephrol. 2024;56:129-135.
    PubMed     Abstract available
    
    
    November 2023
47. BEIJERT IJ, Hentschel AE, Brundl J, Comperat EM, et al
    Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis?
    Int Urol Nephrol. 2023 Nov 19. doi: 10.1007/s11255-023-03867.
    PubMed     Abstract available
    
    
    
48. GERCEK O, Keles I, Saritas TB, Koyuncu B, et al
    Effect of obturator nerve block during transurethral resection of bladder tumors on the disease recurrence, progression and surgery outcomes.
    Int Urol Nephrol. 2023;55:2765-2772.
    PubMed     Abstract available
    
    
    
49. MIYAKE M, Nishimura N, Nishioka Y, Fujii T, et al
    Clinical impact of the intensity of follow-up cystoscopy in patients with high-risk non-muscle-invasive bladder cancer.
    Int Urol Nephrol. 2023 Nov 1. doi: 10.1007/s11255-023-03851.
    PubMed     Abstract available
    
    
    October 2023
50. KOBERLE B, Usanova S, Piee-Staffa A, Heinicke U, et al
    Strong apoptotic response of testis tumor cells following cisplatin treatment.
    Int Urol Nephrol. 2023 Oct 27. doi: 10.1007/s11255-023-03825.
    PubMed     Abstract available
    
    
    
51. WEI C, Deng C, Dong R, Hou Y, et al
    Multi-omics analysis reveals critical metabolic regulators in bladder cancer.
    Int Urol Nephrol. 2023 Oct 26. doi: 10.1007/s11255-023-03841.
    PubMed     Abstract available
    
    
    
52. PAZIR Y, Esmeray A, Caglar U, Erbin A, et al
    Comparison of hyperthermic intravesical chemotherapy and Bacillus Calmette-Guerin therapy in high-risk non-muscle invasive bladder cancer: a matched-pair analysis.
    Int Urol Nephrol. 2023 Oct 25. doi: 10.1007/s11255-023-03849.
    PubMed     Abstract available
    
    
    
53. GERCEK O, Ulusoy K, Yazar VM, Topal K, et al
    Effects of delayed diagnosis on tumor size, stage and grade in bladder cancer.
    Int Urol Nephrol. 2023 Oct 17. doi: 10.1007/s11255-023-03829.
    PubMed     Abstract available
    
    
    
54. KHALIFA SE
    Immunohistochemical expression of CD117/KIT, HER2, and Erbeta in schistosomal and non-schistosomal urothelial carcinoma of Egyptian patients.
    Int Urol Nephrol. 2023;55:2473-2481.
    PubMed     Abstract available
    
    
    September 2023
55. KAYAR R, Bastug Y, Tokuc E, Topaktas R, et al
    Pan-immune-inflammation value as a prognostic tool for overall survival and disease-free survival in non-metastatic muscle-invasive bladder cancer.
    Int Urol Nephrol. 2023 Sep 29. doi: 10.1007/s11255-023-03812.
    PubMed     Abstract available
    
    
    
56. XIAOQIN Z, Zhouqi L, Huan P, Xinyi F, et al
    Development of a prognostic signature for immune-associated genes in bladder cancer and exploring potential drug findings.
    Int Urol Nephrol. 2023 Sep 23. doi: 10.1007/s11255-023-03796.
    PubMed     Abstract available
    
    
    
57. YOU C, Li Q, Qing L, Li R, et al
    Device-assisted intravesical chemotherapy versus bacillus Calmette-Guerin for intermediate or high-risk non-muscle invasive bladder cancer: a systematic reviewer and meta-analysis.
    Int Urol Nephrol. 2023 Sep 2. doi: 10.1007/s11255-023-03765.
    PubMed     Abstract available
    
    
    
58. OSMAN Y, Elawdy M, Taha DE, Zahran MH, et al
    Bladder perforation as a complication of transurethral resection of bladder tumors: the predictors, management, and its impact in a series of 1570 at a tertiary urology institute.
    Int Urol Nephrol. 2023;55:2161-2167.
    PubMed     Abstract available
    
    
    
59. WANG IK, Yu TM, Yen TH, Lin CL, et al
    Comparison of the risks of renal cell carcinoma or urothelial cancer between hemodialysis and peritoneal dialysis patients.
    Int Urol Nephrol. 2023;55:2267-2274.
    PubMed     Abstract available
    
    
    August 2023
60. ASSEM A, Kassem A, Sherif M, Lotfi A, et al
    Safety, feasibility, and quality of thulium laser en-bloc resection for treatment of non-muscle invasive bladder cancer.
    Int Urol Nephrol. 2023 Aug 28. doi: 10.1007/s11255-023-03752.
    PubMed     Abstract available
    
    
    
61. KIM SH, Choi BG, Oh JS, Chun HJ, et al
    Upper tract heparin instillation for maintenance of ureteral stent patency.
    Int Urol Nephrol. 2023;55:1893-1897.
    PubMed     Abstract available
    
    
    
62. OPPOLZER IA, Riester J, Buttner R, Burger M, et al
    Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors.
    Int Urol Nephrol. 2023;55:1943-1949.
    PubMed     Abstract available
    
    
    
63. WANG Z, Yang Z, Qu C, Li J, et al
    Natural killer cells strengthen antitumor activity of cisplatin by immunomodulation and ameliorate cisplatin-induced side effects.
    Int Urol Nephrol. 2023;55:1957-1970.
    PubMed     Abstract available
    
    
    July 2023
64. MOEEN AM, Faragallah MA, Zarzour MA, Elbehairy AA, et al
    Ileal conduit versus single stoma uretero-cutanoustomy after radical cystectomy in patients >/= 75 years; which technique is better? a prospective randomized comparative study.
    Int Urol Nephrol. 2023;55:1719-1726.
    PubMed     Abstract available
    
    
    June 2023
65. KABA M, Pirincci N, Demir M, Kaba S, et al
    The relationship between microRNAs and bladder cancer: are microRNAs useful to predict bladder cancer in suspicious patients?
    Int Urol Nephrol. 2023 Jun 20. doi: 10.1007/s11255-023-03666.
    PubMed     Abstract available
    
    
    
66. SLUSARCZYK A, Zapala P, Olszewska-Slusarczyk Z, Radziszewski P, et al
    The prediction of cancer-specific mortality in T1 non-muscle-invasive bladder cancer: comparison of logistic regression and artificial neural network: a SEER population-based study.
    Int Urol Nephrol. 2023 Jun 6. doi: 10.1007/s11255-023-03655.
    PubMed     Abstract available
    
    
    
67. YILMAZ H, Cinar NB, Avci IE, Akdas EM, et al
    Evaluation of comprehensive complication index versus Clavien-Dindo classification in prediction of overall survival after radical cystectomy.
    Int Urol Nephrol. 2023;55:1459-1465.
    PubMed     Abstract available
    
    
    May 2023
68. FU W, Liu D, Xiong Y, Liu C, et al
    The comparison between contrast-enhanced ultrasound and contrast-enhanced magnetic resonance imaging in diagnosing bladder urothelial carcinoma.
    Int Urol Nephrol. 2023;55:1073-1079.
    PubMed     Abstract available
    
    
    April 2023
69. NISHIHARA D, Kijima T, Arai K, Kamai T, et al
    Increased co-expression of stromal HHLA2 and fibroblast activation protein in upper tract urothelial carcinoma.
    Int Urol Nephrol. 2023;55:867-874.
    PubMed     Abstract available
    
    
    March 2023
70. GRIZZI F, Hegazi MAAA, Taverna G
    Letter to the editor re: "assessing bladder cancer prognosis through circulating tumor cell analysis and Ki-67 measurement".
    Int Urol Nephrol. 2023 Mar 3. doi: 10.1007/s11255-023-03538.
    PubMed    
    
    
    
71. DEWITT-FOY ME, Anele UA, Accioly JPE, Sharpe MG, et al
    Cancer risk in bladder diverticula: a large institutional analysis of risk and management.
    Int Urol Nephrol. 2023;55:541-546.
    PubMed     Abstract available
    
    
    
72. QIU Y, Zhang X, Dong Z, Zhang Y, et al
    Comparable survival benefits of partial ureterectomy to radical nephroureterectomy in non-metastatic ureter carcinoma: a population-matched study.
    Int Urol Nephrol. 2023;55:579-588.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.